Introduction
============

Laryngeal squamous cell carcinoma (LSCC) remains a prevalent disease, accounting for over 150, 000 new cases annually across the world^[@B1]^. Previous clinical trials in LSCC demonstrated the potential for non-surgical, organ-preservation treatment options for LSCC, with similar survival rates to surgery^[@B2],[@B3]^. While these initial organ-preserving paradigms have gradually become the predominant treatment choice for LSCC^[@B4]^, no new treatment options have surfaced in the ensuing decades. For recurrent LSCC after chemotherapy, radiation, or surgery, treatments are limited. This is particularly concerning given the continued poor survival in advanced or recurrent LSCC, where 5-year survival is less than 50%^[@B5]^ and has not improved in decades^[@B6]^.

Whole exome and genome sequencing studies have recently provided valuable insight into dysregulated pathways and potential drivers of disease in multiple cancers, including head and neck cancers^[@B7]-[@B10]^. These early studies have identified novel genetic mutations and pathway dysregulations across a variety of head and neck cancers. Importantly, LSCCs have constituted a significant portion of the tumors in these studies.

Cancer treatment is entering an exciting new era, combining the information gained from next-generation sequencing studies with targeted therapeutics to allow for models of personalized cancer care. Indeed, cancer sequencing and targeted therapy trials are being launched globally, and with some encouraging initial results^[@B11]-[@B13]^. LSCC may prove to be an ideal model for further investigation into personalized targeted therapies given its successful history in response to nonsurgical techniques, previous paradigms for treatment stratification^[@B14]^, and the need to improve survival in this important cohort.

Here, we will discuss the important history of LSCC as a model system for organ preservation, current knowledge of the genomic landscapes, targeted therapies for LSCC, and potential strategies for developing stratified, personalized treatment strategies for LSCC.

Historical treatment of LSCC
============================

For early stage LSCC, single modality therapy (surgery or radiation) achieves cure for a majority of patients. However, patients with locally advanced disease had historically required total laryngectomy followed by adjuvant radiation as the gold standard treatment. Unfortunately, many of these surgeries are accompanied by significant morbidity and many patients are left with significant swallowing difficulties, communication difficulties, and poor cosmetic outcomes^[@B15]^. Thus, in the 1990s, investigations began into equally effective but less morbid therapies.

As a result, the Veterans Affairs (VA) Laryngeal Cancer Study^[@B2]^ was performed. In this prospective randomized controlled study, 332 patients with advanced LSCC were stratified between induction chemotherapy (3 cycles of cisplatin and 5-FU) followed by definitive radiation *vs*. laryngectomy followed by postoperative radiation. Patients in the chemotherapy group were assessed after 2 cycles of chemotherapy; those that showed clinical response to therapy went on to receive one final cycle of chemotherapy followed by radiation. Those that had no response to therapy or disease progression after 2 cycles went on to immediate laryngectomy and then post-operative radiation. There was no difference in two-year survival between the chemotherapy and surgery groups, and laryngeal function was preserved in 64% of the patients in the chemotherapy group. This study established that organ preservation in LSCC was a feasible goal of treatment, while still providing equivalent overall survival.

These findings were confirmed with data from a randomized study in Europe (EORTC trial 24891)^[@B16]^, where patients with cancers of the hypopharynx underwent either induction chemotherapy consisting of cisplatin and 5-FU followed by irradiation, or surgical resection followed by post-operative radiotherapy. In this study, again overall survival was equivalent, and laryngeal preservation was achieved in greater than 50% of patients after 5 years. A third study (RTOG 91-11)^[@B17]^ compared concurrent chemotherapy and radiation, induction chemotherapy followed by radiation, and standard radiation therapy. This study found that laryngeal preservation was significantly higher in patients receiving concurrent chemoradiation. It is important to note this study did exclude large volume T~4~ tumors with cartilage invasion or extension into the base of the tongue. Finally, investigators at the University of Michigan studied the utility of a single cycle of induction chemotherapy in LSCC as stratification for further treatment in a phase 2 clinical trial^[@B14]^. Over 75% of patients had response to induction chemotherapy, and overall larynx preservation was achieved in 70% of patients. This study verified that paradigms of treatment stratification could be utilized in LSCC.

These trials together demonstrated the efficacy of combined chemotherapy and radiation therapy in treating locally advanced LSCC while maintaining the functional status of the larynx. Additionally, they showed that treatment with induction chemotherapy did not increase complications for surgical treatment or radiotherapy administered afterwards. Finally, although there was no benefit in overall survival, a significant reduction in the rate of distant metastasis was shown in the chemotherapy group as compared with primary surgery or radiation therapy alone^[@B2],[@B16]-[@B19]^.

Although there was significant improvement in organ preservation gained by treatment with induction chemotherapy, unfortunately overall outcomes in LSCC remain poor. In the European study, disease free survival at 5 years remained at 25% and 27% for the chemotherapy arm and immediate surgery arm respectively^[@B16]^. Additionally, patients who responded poorly to chemotherapy were likely to respond poorly to radiation^[@B20]^. As such, research began into molecular markers to predict radiosensitivity and chemo sensitivity in order to better personalize therapy and more accurately predict which patients would be eligible for laryngeal preservation.

Several studies have evaluated various molecular biomarkers in an attempt to better predict a response to therapy. Malecki^[@B21]^ looked at EGFR, p53, and Ki-67, which are biomolecular markers found to be altered in patients with head and neck squamous cell carcknoma (HNSCC). In his retrospective trial, only patients without the presence of EGFR expression were noted to have a significantly improved response to induction chemotherapy. In LSCC specifically, it has been recently found that levels of BAK, a gene involved in apoptosis, is associated with response to induction chemotherapy. The same study identified cyclin D1 as a predictor of LSCC overall and disease-specific survival, and overexpression of EGFR as associated with risk of death^[@B22]^.

These biomarker studies have led to clinical trials to evaluate novel therapies with the potential to improve outcomes in LSCC. For examples, we previously showed that AT-101, which inhibits the anti-apoptotic genes Bcl-2 and Bcl-XL, effectively blocks proliferation in LSCC models^[@B23]^ and have now initiated an ongoing trial specifically targeted LSCC evaluating the use of AT-101, in combination with induction chemotherapy with platinum and docetaxel (NCT01633541). Further combinations of traditional chemotherapy, radiation and targeted therapies may be applicable for LSCC. While traditional biomarker studies have been limited in identifying additional targetable options, recent whole-genome sequencing studies have shed more light into potential key pathways in LSCC.

Genetic landscape of LSCCs
==========================

Along with the possibility of identifying additional biomarkers of LSCCs, genomic sequencing offers the potential to identify drivers of tumor genesisand targets for new therapy. Initial exome sequencing studies have already produced valuable insights into the underlying genetic processes, nominating multiple pathways as potential targets for LSCC treatment.

Common mutations and copy number variations
===========================================

Initial exome-sequencing studies by Agrawal et al.^[@B7]^ and Stransky et al.^[@B8]^ contained some LSCCs in their chosen HNSCC cohort (*n*=2 and *n*=15, respectively), but the smaller sample size did not give a broad view of genetic alterations in LSCC. The Cancer Genome Atlas (TCGA) has now whole-genome sequenced 29 HNSCC tumor-normal pairs (low coverage, 30x) and whole exome sequenced 279 HNSCC tumor-normal pairs (high coverage), of which 72 are primary LSCCs^[@B9]^. These LSCC samples are predominantly Caucasian (*n*=57, 79.2%), male (*n*=58, 80.6%), and older (mean age=61). Additionally, most patients had a smoking history (*n*=50, 69.4%) and were diagnosed at Stage III or IV (*n*=55, 76.4%)^[@B9]^, with very few epidemiologically low risk patients in the cohort^[@B24]^. The initial studies by Agrawal et al.^[@B7]^ and Stransky et al.^[@B8]^ had similar cohort characteristics. Publicly available databases compiling clinical, mutation, and copy number data were used for the analysis of this manuscript^[@B25],[@B26]^.

Previously, evaluating the existence of distinct mutation profiles in LSCCs from other subsites has been limited from lack of power. The significant contribution of the HNSCC cohort from the TCGA has allowed the question to begin to be addressed. Many genes that are frequently mutated are common to all HNSCC subsites such as *TP53, CDKN2A, FAT1,* and *NOTCH1* (**[Table 1](#Table1){ref-type="table"}**). *CASP8*, a gene whose product plays a central role in the cell carrying out apoptosis, is frequently mutated in other HNSCCs. However, *CASP8* has significantly less mutations in LSCCs compared to the other subsites (*P*\<0.005). Studies have suggested that *CASP8* mutations indicate a distinct molecular profile of SCCs^[@B27],[@B28]^, but this subset does not seem to exist in LSCCs. Additionally, mutations in *PIK3CA* trend towards occurring more frequently in LSCCs than other subsites (*P*=0.058), and copy number amplification of 3q26 which contains *PIK3CA* is found at significantly higher frequency in LSCCs compared to other HNSCCs (*P*\<0.001, **[Table 2](#Table2){ref-type="table"}**). Additionally, amplifications of 3q28 and 9q34 occur at significantly higher frequency in LSCCs (*P*\<0.001, *P*\<0.007).

###### 

Common genetic mutations

  Gene       TCGA *n*=71 (%)   Stransky *n*=15 (%)   Total LSCC *n*=88 (%)   Total (non-LSCC) *n*=237 (%)
  ---------- ----------------- --------------------- ----------------------- ------------------------------
  *TP53*     64 (88.9)         9 (60.0)              75 (85.2)               188 (79.3)
  *CDKN2A*   17 (23.6)         1 (6.7)               19 (21.6)               53 (22.4)
  *PIK3CA*   18 (25.0)         1 (6.7)               19 (21.6)^\*^           31 (13.1)
  *FAT1*     14 (19.4)         4 (26.7)              18 (20.4)               53 (22.4)
  *NOTCH1*   13 (18.1)         2 (13.3)              15 (17.0)               44 (18.6)
  *CASP8*    1 (1.4)           0 (0)                 1 (1.1)^\*\*^           29 (12.2)

###### 

Frequent copy number variations

  Cytoband (Gene)              CNV       Larynx *n*=72, %   Non-larynx *n*=172, %
  ---------------------------- --------- ------------------ -----------------------
  3q26 (*PIK3CA, SOX2*)        Amp       37.5\*             12.8
  11q13 (*CCND1, FGF3/4/19*)   Amp       36.1               29.1
  9p21 (*CDKN2A/B*)            Del       31.9               32.0
  3q28 (*TP63, ETV5*)          Amp       34.7\*             12.8
  8q24 (*MYC, PTK2*)           Amp       16.7               12.2
  7p12 (*EGFR*)                Amp       12.5               12.2
  9q34 (*NOTCH1, TRAF2*)       Amp/Del   4.2\*/1.4          0/0

While it is clear that many of the aberrations in HNSCC are common across subsites, differences are beginning to emerge as more LSCC samples are being sequenced. By sequencing more LSCCs, we will begin to understand if these differences are due to anatomical subsite or epidemiologic variation between tumors. Likewise, as genome-wide information continues to become available, no doubt distinct subsets of molecular mechanisms will be identified.

Human papilloma virus (HPV) in LSCC
===================================

The link between HPV status and HNSCC has been well established at some anatomical subsites^[@B29],[@B30]^; for example, HPV appears to be a common initiating event in oropharyngeal SCCs . The oncogenic potential of high-risk HPVs in LSCCs is not as clear. Studies with larger sample sizes (where *n*\>80) over the past 30 years have shown HPV prevalence in LSCC tumors from as low as 1% to as high as 50%^[@B31]^. However, studies have also found HPV DNA in up to 19% of normal laryngeal mucosa samples^[@B32]-[@B35]^, indicating that a significant portion of HPV positive LSCCs that have been reported may be latent HPV infections, and more specific techniques should be used to truly determine HPV positivity. In contrast to many of the PCR-based studies, the HNSCC TCGA project relied on multiple methods of detection including RNA-sequencing and identified only one HPV positive LSCC case (1.4%)^[@B9]^. The low prevalence of HPV in this study indicates that HPV rates may have been historically overestimated in some LSCCs cohorts with similar epidemiology to the TCGA cohort, and unfortunately the low number of samples detected in LSCC will make it difficult to study the extent of the oncogenic role of HPV in LSCC until more studies are performed. This significant variance between studies is most likely due to both the method of detection and the differential rates of HPV infection in each region. For example, HPV DNA PCR assays are capable of detecting very few copies of the viral DNA and some have argued that these assays are too sensitive, able to pick up viral DNA from a transient infection rather than an integrated event^[@B35],[@B36]^.

Consequently, many additional assays have been developed that rely on detecting common downstream events of HPV biology or directly sequencing across genomic insertion sites. For example, when HPV integrates into the genome, early genes E6 and E7 are highly expressed^[@B36]^. E7 then inactivates pRb, causing increased levels of p16^INK4A^ which can be detected by immunohistochemistry^[@B37]^. Thus, using the downstream protein expression of p16 as a surrogate marker for HPV has become a widely acceptable method and clinically relevant method^[@B38]^. Likewise, a second method of detecting HPV integration is to directly sequence the genomic breakpoints between the viral and human genomes. This method is usually cost prohibitive at this point, due to the high cost of whole genome sequencing, but may become more routine in the future. Regardless as the methods for rapid detection and location of HPV insertion sites in the genome improve, so will our understanding of the prevalence and pathogenic role for this virus in LSCC.

Translating genetics into targeted therapies
============================================

The potential to improve patient survival by using genetic information to match optimal treatments can be seen in a growing number of successes in other cancers: imatinib for chronic myelogenous leukemia^[@B39]^, trastuzumab for breast cancer with *ERBB2* amplification^[@B40]^, and erlotinib and gefitinib for lung cancers that express mutant *EGFR*^[@B41]^. Here, we will review a few specific molecular lesions that are altered in a large percentage of LSCC cases and have a similar potential for molecularly driven clinical trials.

PI3K pathway
============

*PIK3CA* mutations and amplifications frequently occur in LSCCs. *PIK3CA* encodes p110α, the alpha catalytic subunit to the phosphoinositide 3-kinase (PI3K) which plays a central role in pathways involved in cell growth, survival, and metabolism^[@B42]^. PI3K receives signals from activated receptor tyrosine kinases such as EGFR and VEGFRs, and phosphorylates the lipid PIP~2~ on the cell membrane to create PIP~3~. AKT is then activated by PIP­~3~, resulting in a downstream cascade through multiple effectors including GSK-3 and mTOR (**[Figure 1](#Figure1){ref-type="fig"}**). This pathway has been noted to be frequently overactive in other cancers including gastric, breast, and lung^[@B43]^, and developing therapies targeting this pathway are underway^[@B44]^.

![Key components of the PI3K pathway with possible therapeutic targets. Drugs targeting individual components are either in trials as noted, or were effective *in vitro* with cell lines containing *PI3KCA* mutations. The RAS/MEK/ERK pathway, which has been noted to play a role in resistance to PI3K-targeted therapies, is shown.](cbm-13-1-87-1){#Figure1}

The majority of mutations found in *PIK3CA* have been defined as \'hotspot\' mutations, where the specific amino acid residue is recurrently altered in multiple tumortypes^[@B45]^. These hotspot mutations, such as E542K, E545K, and H1047L/R, have functional consequences of increasing the lipid activity resulting in overactive AKT signaling and downstream effector pathway activation^[@B46]^. The over activation of the PI3K pathway in these cancer cells could make the cells reliant on these signals^[@B47]^. For example, Garnett et al.^[@B48]^ found that *PIK3CA* mutations were a significant biomarker of sensitivity for several drugs targeting the PI3K pathway after screening over 600 cancer cell lines, including 23 HNSCC lines, against 130 drugs at clinical and preclinical stages. HNSCC cell lines with hotspot *PIK3CA* mutations demonstrated sensitivity to PI3K/mTOR inhibitors compared to *PIK3CA* wildtype cells, in both *in vitro*^[@B49]^ and *in vivo* models^[@B50]^. These preclinical results are now being tested in early clinical trials for patients with a variety of advanced cancers, including HNSCCs. In a phase 1 trial, patients containing *PIK3CA* mutations had significantly greater partial response rates to PI3K/AKT/mTOR therapy (6/17, 35%) than those without *PIK3CA* mutations (6/241, 6%)^[@B51]^. A following early-phase trial indicated that only the H1047R mutation predicted partial response (6/16, 38%) compared to other *PIK3CA* mutations (5/50, 10%) or *PIK3CA* wildtype (23/174, 13%)^[@B52]^. However, this study also noted that other hotspot *PIK3CA* mutations, such as E542K and E545K, had a strong association with *KRAS* mutations whereas the H1047R mutation did not. As members of the Ras signaling pathway (*KRAS, HRAS)* have been known to mediate resistance to PI3K inhibition^[@B53],[@B54]^, it is unsurprising that patients with both gene mutations may not respond to PI3K-targeting monotherapies. Notably, *KRAS* mutations are rare in HNSCCs^[@B55]-[@B57]^, and there are no *KRAS* mutations present in the recent exome sequenced LSCCs^[@B7]-[@B9]^. *HRAS* mutations occur with more prevalence^[@B50]^, and of the 2 *HRAS* mutations in sequenced LSCCs both occur in tumors with additional *PIK3CA* hotspot mutations^[@B11],[@B12]^. However, 68.4% (13/19) of the *PIK3CA* mutations in LSCCs are hotspot mutations without Ras mutations, and PI3K-targeted therapies could be a well-matched choice for this patient population.

In contrast, amplification of 3q26 with the *PIK3CA* gene has not been found to indicate sensitivity to PI3K-targeted therapy^[@B48],[@B49]^. It is still unclear how the amplification of the *PIK3CA* gene affects the signaling of the PI3K pathway. While it has been shown that amplification of *PIK3CA* correlates with increased mRNA and protein expression of p110α^[@B58]^, it does not necessarily lead to increased levels of phosphorylated Akt and mTOR as would be expected for increased pathway activation^[@B49]^. Given the significant amplification of 3q26 in LSCCs specifically, it is crucial to understand the effects this amplification has on tumorigenesis whether *PIK3CA* or another nearby gene is the cause.

EGFR & HER2
===========

The important role that the epidermal growth factor receptor (EGFR) plays in HNSCCs has been known for several decades^[@B59],[@B60]^ as it has been shown to be overexpressed in \>90% of HNSCCs. A tyrosine kinase receptor, EGFR belongs to the ERBB family of cell-surface receptors. Upon ligand binding to the receptor, EGFR homodimerizes or heterodimerizes with other ERBB family receptors such as HER2 and initiates a signaling cascade^[@B61]^. Potential activated pathways include Ras-MEK and PI3K/AKT/mTOR as discussed above, as well as signal transducers and activators of transcription (STATs). EGFR signaling can contribute to tumorigenesis by driving cell proliferation, evasion of apoptosis, angiogenesis, and metastasis^[@B62]^.

Consistent with the molecular role of EGFR, cetuximab, a monoclonal antibody targeting EGFR, is currently the only approved targeted molecular therapeutic for HNSCCs. The combination of cetuximab and radiation therapy has been shown to extend patient survival by 19.3 months compared to radiation alone in patients with recurrent or metastatic disease^[@B63]^. However, contrasting the clear story of *EGFR* mutations in lung adenocarcinomas predicting sensitivity to EGFR-targeted therapies^[@B41]^, there are still no biomarkers that predict response to cetuximab.

Part of the reason for the lack of biomarkers in HNSCC as compared to lung adenocarcinomas may be due to the differential genetic lesions. On contrast to lung cancers where *EGFR* mutation is a common event, *EGFR* mutations are rare in HNSCCs (13/279, 4.7%)^[@B9]^, while amplifications have been reported to vary between 10%-30%^[@B64]^. In HNSCC TCGA data, LSCCs had a similar frequency of amplification as other subsites at around 12% (**[Table 2](#Table2){ref-type="table"}**). However, amplification of *EGFR* correlated with worse overall survival in LSCCs specifically^[@B65]^. Additionally, in a phase 2 trial advanced LSCC patients received a single cycle of induction chemotherapy before stratification into surgery and radiation or chemoradiation treatments. Here, EGFR expression predicted increased risk of death^[@B22]^. While there is no evidence for any biological difference in EGFR signaling between HNSCC subsites, the prognostic role of EGFR in LSCCs specifically suggests an especially critical role of this receptor and pathway.

Activating similar pathways is the HER2 receptor which heterodimerizes with EGFR as well as other members of the ERBB family. While *HER2* amplifications seem rare (3/72, 4.2%)^[@B9]^, experiments in LSCC cell lines have shown response to anti-HER2 therapy in models with HER2 over-expression^[@B66]^. Targeting HER2 in this distinct subset of patients looks promising as research continues, and significant improvements to patient survival might be made through focusing on targeting this pathway for LSCCs.

Notch signaling
===============

The frequency of *NOTCH1* mutations in HNSCCs was surprising when first discovered, additionally so as many of the mutations were predicted to be loss-of-function^[@B7]^. Traditionally, the Notch signaling pathway has been studied in an oncogenic role as activating mutations in *NOTCH1* have been shown to significantly contribute to tumorigenesis for several malignances including chronic lympocytic leukemia (CLL)^[@B67]^ and prostate cancer^[@B68]^. However, solid tumors such as lung squamous cell carcinoma, cutaneous squamous cell carcinoma^[@B69]^, and HNSCC display loss-of-function mutations indicative of Notch signaling has playing a role as a tumor suppressor.

The Notch signaling pathway is a direct cell-cell communication network, where a signaling cell displays a ligand that binds and activates the receptor on the receiving cell membrane. There are four receptors, NOTCH1-4, which upon activation are cleaved by gamma secretase, following which the intracellular domain (ICD) of the receptor is translocated to the nucleus resulting in transcriptional activation of target genes.

In keratinocytes, it has been shown that Notch activity controls cell cycle exit as well as commitment to differentiation^[@B70]^, where loss of *NOTCH1* promotes tumorigenesis^[@B71]^. Importantly, the loss of Notch signaling leads to an accumulation of β-catenin expression and an increase in Wnt pathway activity^[@B72]^, and Wnt signaling has been shown to have an oncogenic role in multiple cancers^[@B73]^. The possibility of addiction to Wnt signaling resulting from a loss of Notch signaling creates the opportunity for therapeutic intervention. Indeed, the *PORCN* inhibitor (this gene palmitoylates WNT ligands enabling their secretion into the tumor niche) called WNT974 has shown inhibition of growth of HNSCC models with loss-of-function mutations in *NOTCH1*^[@B74]^. Accordingly, we have now opened a phase 2 clinical trial for metastatic HNSCC patients that will be enriched for NOTCH-deficient cancer to receive WNT974 (NCT02649530). As 17% of LSCCs contained mutations in *NOTCH1*, WNT974 is a potential targeted therapeutic that will be evaluated for further clinical advancement.

In contrast to inactivating NOTCH mutations, a small subset of studies have also reported that over-activation of Notch signaling can contribute to HNSCC^[@B75]^. As LSCCs have a significant amplification of *NOTCH1* compared to other HNSCC subsites (*P*\<0.007, **[Table 2](#Table2){ref-type="table"}**), Notch signaling may also act as an oncogene for a defined subset. A role as both an oncogene and tumor suppressor suggests Notch signaling can have a bimodal effect in HNSCCs, dependent on timing and order of mutations. These roles will need to be further elucidated to directly target Notch signaling or any of its modulators.

Cyclin D1 (CCND1)
=================

The *CCND1* gene encodes cyclin D1, a member of a highly conserved cyclin family. Cyclin D1 regulates cyclin-depending kinases (CDKs) 4 and 6 which control the G~1~/S phase transition of the cell cycle. The amplification or gain of 11q13, which contains *CCND1*, is a frequent event in LSCCs specifically (36.1%, **[Table 2](#Table2){ref-type="table"}**). Importantly, high expression of cyclin D1 correlated with increased risk of death in advanced LSCC patients^[@B22]^. The efficacy of CDK inhibitors to prevent cell cycle progression by overexpressed cyclin D1 is an area of active investigation in LSCC. Currently, multiple clinical trials investigating CDK4/6 inhibitors in HNSCC are underway^[@B76]^, and some of these inhibitors such as palbociclib have already shown efficacy in other cancers^[@B77]^. For example, in one phase 1 trial of recurrent and/or metastatic HNSCC, the CDK4/6 inhibitor LEE011 is being evaluated in combination with cetuximab and the results will soon be published (NCT02429089). The extent of correlation between high expression of cyclin D1 and patient response to CDK inhibitors will be critical to clarifying the potential biomarker role of *CCND1* amplification status. Consequently, much research remains for *CCND1* amplified HNSCCs.

Immunotherapy
=============

An additional novel treatment option for LSCC that has rapidly advanced in recent years involved immune modulating agents. Immune dysregulation and escape have been increasingly recognized as a hallmark of cancer and potential therapeutic target over the past several years^[@B78]^. It is believed that the adaptive immune system recognizes and eliminates pre-malignant cells. Progressive derangements in the immune system driven by transformed cells gradually leads to immune escape and widespread tumor proliferation^[@B79]^. Observed derangements include inflammatory cytokine expression and activation of inflammatory transcription factors in tumor cells^[@B80],[@B81]^. LSCC and other subsites of HNSCC have been demonstrated to be markedly immunosuppressive via numerous mechanisms, including downregulation of antigen presenting via human leucocyte antigen (HLA) class I molecules^[@B9],[@B82]-[@B84]^, development of T-cell tolerance to overexpressed antigens^[@B85],[@B86]^, inhibitory cytokine production^[@B87],[@B88]^, and increased programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) expression^[@B89]-[@B91]^.

Based on these preclinical findings, numerous potential targets and interventions have been proposed. Monoclonal antibodies targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) (ipilimumab), PD-1 (pembrolizumab), or PD-L1 (nivolumab) have been developed with the goal of manipulating mechanisms of tumor escape and eliciting an adaptive immune system response targeted towards the tumor^[@B92]^. Therapy in patients refractory to standard therapy has been well-tolerated and yielded favorable response rates^[@B93]-[@B100]^. However, of more excitement, there are a few patients that appear to achieve lasting complete disease response. These durable responses are being observed in patients who previously would have had a rapidly terminal disease. PD-1/PD-L1 inhibitors have now been approved for metastatic non-small cell lung cancer, renal cell cancer, and melanoma.

Given the clinical efficacy in other malignancies and the immunologic underpinnings, immunotherapy is an avenue of significant interest in LSCC. Various modalities are under development, including vaccine therapy and targeted monoclonal antibodies. Although many of these trials are ongoing, preliminary data has been presented of the Phase 1/2 KEYNOTE-012, where a cohort of 132 HNSCC patients with unresectable recurrent or metastatic tumors were treated with the PD-1 inhibitor pembrolizumab. This cohort was heavily pretreated with 59% of patients having received 2 or more previous lines of therapy for recurrent or metastatic disease. The overall response rate was observed to be 24.8% with an additional 24.8% achieving stable disease. At the time of the interim report, the median duration of response was not reached and 86% of responding patients appeared to have an ongoing response^[@B101]^. Correlative analysis suggested that an inflamed genotype gene expression was able to predict 6 month progression free survival and response to anti-PD-1 therapy^[@B102]^.

A few trials are examining the incorporation of immunotherapy in the management of locoregional HNSCC, including LSCC. These include neoadjuvant vaccine administration (NCT02002182, NCT02609386), concomitant cetuximab and ipilimumab with intensity modulated radiation therapy (IMRT) (NCT01860430), and addition of nivolumab to concomitant cisplatin and IMRT (RTOG3504). Although the majority of trials are targeting recurrent or metastatic HNSCC (all subsites), the preliminary promise of immunotherapy in advanced and recurrent HNSCC cases suggest that LSCC patients could benefit from this novel therapeutic approach.

Overcoming challenges for targeted therapy
==========================================

While targeted therapies have had several clinical successes in other cancers, these are often in tumors with relatively few \"actionable\" aberrations. In contrast to tumors with low genetic complexity, the relatively high number genomic alterations in LSCCs coupled with the complex level of intra-tumor genetic heterogeneity will make distilling the critical pathways disrupting tumor growth difficult to identify. Moving forward, additional LSCC genetic information and models for tumors associated with both under-represented epidemiologic-risk groups and genetic landscapes are needed to improve our ability to predict the response of tumors to genetic lesion-matched therapeutics.

As mentioned above, the available genetic information for LSCC tumors is currently largely limited to previously untreated, stage III/IV tumors from Caucasian patients with a history of tobacco and/or alcohol use. Genetic information from untreated early stage (I/II) LSCC tumors would be beneficial to isolating initial aberrational events that drive tumorigenesis. Likewise, as patients are most likely to enroll in personalized medicine trials with advanced or recurrent tumors, genomic landscapes of advanced tumors following relapse from frontline therapy would be the most beneficial for designing novel interventional strategies. Unfortunately, large sequencing studies of tumors from previously treated, advanced LSCCs have not yet been published, with the exception of a few small cohorts demonstrating that advanced and recurrent LSCCs typically have higher numbers of genetic aberrations than untreated counterparts^[@B10]^. These studies are critical because they demonstrate proof-of-principle that the genomic landscape of LSCCs evolve with therapeutic course. Thus, an important goal for the immediate future is to build a comprehensive understanding of the genetic and molecular interaction between the highly recurrent disruptive genomic events found at each stage of tumor progression.

Importantly, several LSCC models already exist that can be used to dissect the genetic and molecular mechanisms of LSCC pathogenesis, but these are also limited to a few epidemiologic subsets and few genetic landscapes. For example, there are LSCC cell line models from primary, metastatic, and recurrent tumors^[@B103]^, including two pairs of primary and metastatic cell lines from the same patient^[@B104]^ and an HPV-positive line^[@B105]^ (**[Table 3](#Table3){ref-type="table"}**). While the value of these existing cell lines is clear, more models of various stages and pre/post-treatment status consistent with normal interventional progression are still needed to fully explore therapeutic responses at various points in the normal pathogenic course.

###### 

LSCC cell line models

  Cell Line                  Age   Gender   TNM       Stage   Subsite        Type of Lesion   HPV status
  -------------------------- ----- -------- --------- ------- -------------- ---------------- ------------
  Paired                                                                                      
  UMSCC-10A                  57    M        T3N0M0    III     True cord      Primary          \-
  UMSCC-10B                  58    M        T3N1M0    III     Lymph node     Metastasis       \-
  UMSCC-17A                  47    F        T1N0M0    I       Supraglottis   Primary          \-
  UMSCC-17B                  47    F        T1N0M0    I       Soft tissue    Metastasis       \-
  Primary                                                                                     
  UMSCC-11A                  65    M        T2N2aM0   IV      Epiglottis     Primary          \-
  UMSCC-23                   36    F        T2 N0M0   II      Supraglottis   Primary          \-
  UMSCC-28                   61    F        T1 N0M0   I       True cord      Primary          \-
  UMSCC-41                   78    M        T2N1M0    III     Arytenoid      Primary          \-
  UMSCC-81B                  53    M        T2 N0M0   II      True cord      Primary          \-
  UMSCC-105                  51    M        T4 N0M0   IV      True cord      Primary          Positive
  Recurrent and metastatic                                                                    
  UMSCC-12                   71    M        T2N1M0    III     Larynx         Recurrence       \-
  UMSCC-13                   60    M        T3N0M0    III     Esophagus      Recurrence       \-
  UMSCC-25                   50    M        T3N0M0    III     Neck           Metastasis       \-

In addition to cell lines, models in which surgically excised tissue from patients is implanted into immunocompromised mice called patient-derived xenograft (PDX) models have recently gained traction as powerful tools for assessing therapeutic responses in pre-clinical studies. In fact, HNSCC studies using PDX models in this manner have already been used to support the translation of targeted strategies into clinical trials^[@B106]^, supporting the utility of these models. Early studies have indicated that HNSCC PDX models represent parental tumors by histology^[@B107],[@B108]^, gene expression profiles^[@B109]^, single-nucleotide polymorphisms^[@B110]^, copy number variants^[@B110],[@B111]^ and proteome profiles^[@B112]^ and there also has not been an indication that engraftment of the tumor is biased by either genetic or clinical factors, including HNSCC subsite^[@B113]^. Unfortunately the expense as well as the variable grafting rate (30%-80% reported for HNSCC) is currently limiting the wide-spread use^[@B114]^, but once the PDX model is established, the tumor can be propagated and expanded into additional mice for parallel, sequential, and long-term therapeutics experiments^[@B115]^. Moving forward, the establishment and characterization of LSCC PDX models from both untreated and pretreated tumors will be essential for the advancement of therapeutics for different epidemiologic and genetic subsets of LSCC.

Algorithms for integrating LSCC organ preservation/treatment
============================================================

As noted above, LSCC historically has been a unique and successful model for treatment selection and for organ preservation. However, with the current evolving state of genetics and targeted agents in cancer, we will need to revisit treatment algorithms for this disease.

While existing selection paradigms have been focused on objective clinical response to induction chemotherapy^[@B14]^, future goals would be to identify these potential responders to organ-preservation therapy without the need for an induction chemotherapy cycle. Through next generation sequencing studies, we have already identified specific genetic pathways that may be of interest for targeted therapy in LSCC (**[Figure 2](#Figure2){ref-type="fig"}**)^[@B76]^. Further incorporating patient genetic information into treatment algorithms for LSCC could serve to further stratify and improve patient outcomes (**[Figure 3](#Figure3){ref-type="fig"}**). As the cost and turnaround for targeted next-generation sequencing improves, valuable time could be saved to initiation of definitive treatment, and patients could be treated more specifically and effectively.

Specific issues should be considered as treatment algorithms are adapted to include new agents and genomic sequencing. An important decision in use of targeted therapies is whether they should be used irrespective of mutational status (as cetuximab is currently used in HNSCC), or whether targeted therapies should be employed only in those patients with genetic aberrations. Additionally, protocols will need to be designed and implemented investigating these agents in different clinical scenarios (i.e. neoadjuvant *vs.* adjuvant, monotherapy *vs.* combination therapy, early *vs.* late stage tumors, primary *vs.* recurrent tumors, **[Figure 3](#Figure3){ref-type="fig"}**). Likewise, we must consider when and where to add immunotherapy into LSCC treatment algorithms. In a similar fashion to targeted therapy, we must identify predictive biomarkers to allow for treatment stratification^[@B102]^.

Another key group of LSCC patients in need of additional treatment options are those with recurrent disease after both chemoradiation and surgery. These patients have poor outcomes (5-year overall survival 49% and disease-free survival 58%; our unpublished data). Moreover, these recurrences are often untreatable, as patients will have exhausted all other avenues of treatments. Currently, there are no other available options for these patients, and their care is often palliative. Interestingly, patients with recurrent HNSCCs may have different mutational signatures^[@B10]^. Thus, identifying these patients (through predictive genetic biomarkers) and intervening with additional therapies (targeted agents, immunotherapy) earlier in their disease-course may lead to modified treatment algorithms and improve outcomes.

![Major oncogenic mechanisms in LSCC and therapeutic opportunities. Dysregulated pathways common to LSCCs with targeted therapies in clinical trials for HNSCCs are shown^76^. WNT974 targets PORCN thereby blocking Wnt ligand secretion from neighboring cells.](cbm-13-1-87-2){#Figure2}

![Decision algorithm for treating LSCC patients. Current practice is shown with black arrows, with traditional treatments such as surgery/radiation/chemotherapy. The red arrows incorporate HPV status and patient genetics to add targeted treatments or immunotherapy to improve cure rate.](cbm-13-1-87-3){#Figure3}

Currently, targeted therapy clinical trials are aimed towards recurrent and advanced stage cancers. In the future, the possibility of expanding these agents to early-stage tumors will be important. Potentially, early-stage LSCC may be more responsive to targeted therapies, given they may have a lower overall mutational burden, and fewer potential targetable dysregulated driver mutations.

As with all next-generation sequencing trials, ethical considerations must be addressed^[@B116]^. Thus, future programs for personalized medicine in LSCC should have well-established guidelines for pretest counseling on disclosure of genetic information, and have genetic counselors actively involved throughout the process.

Conclusions
===========

With the increasing implementation of next-generation sequencing and personalized medicine protocols for cancer, LSCCs may be a particularly useful and successful model disease for novel treatment paradigms. Given the long history and relative success of LSCC and organ-preservation protocols, there will be an inevitable evolution towards adopting targeted and immune modulating agents for this disease. While identification of prognostic genetic biomarkers, therapeutic targets and models to perform molecular studies specific to LSCC remains incomplete, this field is rapidly advancing. Ultimately, these novel strategies will increasingly be investigated and applied to LSCC, which will hopefully improve both organ preservation and overall survival for patients with this disease.
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